ライフサイエンスコーパス: low-density lipoprotein

1 that triglyceride levels causally influence low-density lipoprotein.

2 re typically present in oxidatively modified low-density lipoprotein.

3 inds both high-density lipoprotein (HDL) and low-density lipoprotein.

4 blood pressure 51.2%; body mass index 33.8%; low-density lipoprotein 31.4%; and waist-to-hip ratio 29

5 ces, -0.35 kg/m(2); 95% CI, -0.62 to -0.07), low-density lipoprotein (4 studies; mean differences, -0

6 Exposure of monocytes to oxidized low-density lipoprotein, 7-ketocholesterol, phorbol 12-m

7 preventing inflammation induced by oxidized low-density lipoprotein and promoting apoptotic cell cle

8 ned significant after adjusting for baseline low-density lipoprotein and statin dose (beta=-0.27; P=0

9 ss 6 to 12 months, including blood pressure, low-density lipoprotein and total cholesterol levels, an

10 tween noncoding rare variants in SLC22A3 and low-density lipoprotein and total cholesterol, associati

11 tiology via extensive associations with very-low-density lipoprotein and triglyceride metabolism.

12 isease who require further reduction in LDL (low-density lipoprotein) and non-HDL-C.

13 tivity and total HDL antioxidant capacity on low-density lipoproteins), and HDL vasodilatory capacity

14 biomarkers, namely, fibrinogen, adiponectin, low-density lipoprotein, and 8-isoprostane.

15 ciated with a significant increase in total, low-density lipoprotein, and high-density lipoprotein (H

16 Serum levels of total cholesterol (TC), TG, low-density lipoprotein, and high-density lipoprotein we

17 resulted in significant reductions in total, low-density lipoprotein, and non-high-density lipoprotei

18 ncreased high-density lipoprotein, decreased low-density lipoprotein, and reduced atherosclerosis.

19 IHD, systolic and diastolic blood pressure, low-density lipoprotein- and total cholesterol, triglyce

20 ocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipop

21 is tempers triglyceride availabiity for very low density lipoprotein assembly and allows homeostatic

22 the CC-genotype was associated with elevated low density lipoprotein cholesterol (LDLc) and total cho

23 burden related to phenotypic FH, defined by low-density lipoprotein cholesterol >/=190 mg/dL, is lik

24 h a third who had residual cholesterol risk (Low-density lipoprotein cholesterol >100 mg/dL).

25 Children with HeFH (age, 6-<18 years) and low-density lipoprotein cholesterol >4.9 mmol/L or >4.1

26 ntion parameters-aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin

27 ncomitant therapies, including patients with low-density lipoprotein cholesterol <70 mg/dl.

28 d with the highest versus lowest quartile of low-density lipoprotein cholesterol (>/= 146 versus </=

29 idence interval, 18-27; P<1.0x10(-4)), lower low-density lipoprotein cholesterol (-12.2 mg/dL; 95% co

30 ipoprotein cholesterol (1.6 [1.2-2.2]), high low-density lipoprotein cholesterol (1.6 [1.1-2.1]), and

31 ]), obesity (3.7 [2.0-7.0]), borderline high low-density lipoprotein cholesterol (1.6 [1.2-2.2]), hig

32 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non

33 oach using only childhood lipid measures for low-density lipoprotein cholesterol (area under the rece

34 Pravastatin lowered low-density lipoprotein cholesterol (change in SD units

35 A and NPHSII, respectively; both p < 0.001), low-density lipoprotein cholesterol (correlation coeffic

36 t showed differential responses in total and low-density lipoprotein cholesterol (decreased in LFHC g

37 For low-density lipoprotein cholesterol (LDL) of 130-159 mg/

38 Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) >/=190 mg/dL

39 se <126 mg/dl, total cholesterol <240 mg/dl, low-density lipoprotein cholesterol (LDL-C) <160 mg/dl,

40 iglycerides (TGs), high-density (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (n=627).

41 haracterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and accelera

42 ma concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipop

43 Serum low-density lipoprotein cholesterol (LDL-C) and high-den

44 ontinuous relationship between reductions in low-density lipoprotein cholesterol (LDL-C) and major ad

45 Increased serum levels of low-density lipoprotein cholesterol (LDL-C) are an indep

46 oring nonfasting lipid assessment may affect low-density lipoprotein cholesterol (LDL-C) estimation.

47 elected individuals with increased levels of low-density lipoprotein cholesterol (LDL-C) have shown m

48 tients with elevated 10-year risk (>5%) or a low-density lipoprotein cholesterol (LDL-C) level of 4.9

49 y statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of les

50 cluding 511 adult patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) levels and h

51 noclonal antibody against PCSK9 that reduces low-density lipoprotein cholesterol (LDL-C) levels by 55

52 itors in patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despi

53 ter transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels witho

54 The primary outcome was the low-density lipoprotein cholesterol (LDL-C) levels.

55 amination of the effects of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovas

56 was shown that intraindividual variation in low-density lipoprotein cholesterol (LDL-C) predicts bot

57 Low-density lipoprotein cholesterol (LDL-C) reductions w

58 exin type 9 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low

59 Median untreated low-density lipoprotein cholesterol (LDL-C) was 239 mg/d

60 vestigated whether the relative reduction in low-density lipoprotein cholesterol (LDL-c) was a good i

61 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

62 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

63 Elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequent

64 Importance: Low-density lipoprotein cholesterol (LDL-C)-lowering all

65 orin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing the

66 preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C).

67 key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C).

68 could be useful for treating high levels of low-density lipoprotein cholesterol (LDL-C).

69 imarily expressed in the liver and regulates low-density lipoprotein cholesterol (LDL-C).

70 one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a cr

71 l/L, LF = -0.31 +/- 0.10 mmol/L; P = 0.024), low-density lipoprotein cholesterol (PY = -0.35 +/- 0.10

72 patients after acute coronary syndrome with low-density lipoprotein cholesterol 50 to 125 mg/dL were

73 igh-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total chole

74 e subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol across diverse patie

75 n/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular e

76 me-wide significant variants associated with low-density lipoprotein cholesterol and coronary heart d

77 The interaction between low-density lipoprotein cholesterol and IHD genetic load

78 creased body mass index, active smoking, and low-density lipoprotein cholesterol and lipoprotein(a) l

79 nsistent relationship between lower achieved low-density lipoprotein cholesterol and lower risk of li

80 s and cumulative exposure to lower levels of low-density lipoprotein cholesterol are not associated w

81 atment to placebo in individuals with normal low-density lipoprotein cholesterol but increased C-reac

82 Unregulated uptake of low-density lipoprotein cholesterol by circulating monoc

83 sult in lifelong exposure to lower levels of low-density lipoprotein cholesterol can provide informat

84 ificantly lower median time-weighted average low-density lipoprotein cholesterol compared with placeb

85 In secondary analyses conditioning on low-density lipoprotein cholesterol concentration, the e

86 t-day humans, including variants involved in low-density lipoprotein cholesterol concentrations, schi

87 s for neurocognitive impairment per 20 mg/dL low-density lipoprotein cholesterol decrements were 1.02

88 s in the face of lower levels of circulating low-density lipoprotein cholesterol in mice lacking miR-

89 A1c was -0.022 +/- 0.53%; however, total and low-density lipoprotein cholesterol increased significan

90 CI, -0.82 to -0.16]; 23 trials [n = 58022]), low-density lipoprotein cholesterol level (-2.58 mg/dL [

91 , but approval rates did not vary by patient low-density lipoprotein cholesterol level nor statin use

92 The overall mean low-density lipoprotein cholesterol level was 26.5% lowe

93 ter publication) in the cohort with elevated low-density lipoprotein cholesterol levels (ie, >/=190 m

94 , including reductions in blood pressure and low-density lipoprotein cholesterol levels and improveme

95 atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol levels of at least 7

96 counted net price of $10311 in patients with low-density lipoprotein cholesterol levels of at least 8

97 Individuals with elevated fasting low-density lipoprotein cholesterol levels were also ran

98 Higher low-density lipoprotein cholesterol levels were not asso

99 sment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with atorvast

100 iagnoses, lipid-lowering medication use, and low-density lipoprotein cholesterol levels.

101 levels and increases in serum creatinine and low-density lipoprotein cholesterol levels.

102 24% (95% CI, 8-37; P=0.004) despite similar low-density lipoprotein cholesterol lowering.

103 on the potential long-term effects of lower low-density lipoprotein cholesterol on neurocognitive im

104 of early initiation of statin treatment for low-density lipoprotein cholesterol reduction in childre

105 NA that regulates LDLR and may contribute to low-density lipoprotein cholesterol response to statin t

106 eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribin

107 eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribin

108 sed on benefits estimated from reductions in low-density lipoprotein cholesterol that occurred in PCS

109 Low-fat diets tend to improve low-density lipoprotein cholesterol the most, while lowe

110 Intensive low-density lipoprotein cholesterol therapy with ezetimi

111 ing family history, more stringent age-based low-density lipoprotein cholesterol thresholds, or alter

112 herosclerotic Cardiovascular Risk in Adults, low-density lipoprotein cholesterol treatment thresholds

113 The median admission low-density lipoprotein cholesterol was lower among pati

114 s coronary intervention, and higher level of low-density lipoprotein cholesterol were independent pre

115 Moreover, lowering of low-density lipoprotein cholesterol with evolocumab redu

116 Low-density lipoprotein cholesterol(LDL-C) is a well est

117 (A), biomarkers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein cholesterol), and clinical varia

118 -8 mg/dl for total cholesterol, -8 mg/dl for low-density lipoprotein cholesterol, +8 mg/dl for remnan

119 ed on 58 single-nucleotide polymorphisms for low-density lipoprotein cholesterol, 71 single-nucleotid

120 nt of saturated with unsaturated fats lowers low-density lipoprotein cholesterol, a cause of atherosc

121 ype natriuretic peptide, and lower levels of low-density lipoprotein cholesterol, adiponectin, lipopr

122 with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure.

123 ntrol subjects and had higher triglycerides, low-density lipoprotein cholesterol, and HbA1c and lower

124 pe 9 (PCSK9) inhibitors substantially reduce low-density lipoprotein cholesterol, but it is presently

125 nic profile scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, coronary artery dis

126 ng insulin, triglyceride, total cholesterol, low-density lipoprotein cholesterol, fasting glucose, di

127 diabetes duration, systolic blood pressure, low-density lipoprotein cholesterol, hemoglobin A1c, alb

128 ated to cardiovascular disease risk factors: low-density lipoprotein cholesterol, high-density lipopr

129 high-density lipoprotein cholesterol, lower low-density lipoprotein cholesterol, lower triglycerides

130 Current smoking, low-density lipoprotein cholesterol, multivessel CAD, di

131 Low-density lipoprotein cholesterol, non-high-density li

132 In multivariable analysis, older age, higher low-density lipoprotein cholesterol, pack per year of sm

133 Also, total cholesterol, low-density lipoprotein cholesterol, triacylglycerol, gl

134 Application of SCOPA to two GWAS of high-and low-density lipoprotein cholesterol, triglycerides and b

135 1 microbe intervention in rats reduced serum low-density lipoprotein cholesterol, triglycerides and t

136 ex, fasting plasma glucose, glycohemoglobin, low-density lipoprotein cholesterol, triglycerides, high

137 ensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotein cholesterol, where NT-proBNP and

138 acebo, in addition to effective statin-based low-density lipoprotein cholesterol-lowering treatment.

139 is-methylation quantitative trait loci for a low-density lipoprotein cholesterol-related differential

140 n, blood pressure, albuminuria, smoking, and low-density lipoprotein cholesterol.

141 ulating triglycerides and a 12% reduction in low-density lipoprotein cholesterol.

142 ent-specific ratios of triglycerides to very low-density lipoprotein cholesterol.

143 lycerols, apolipoproteins A-I and B, or very low-density lipoprotein cholesterol.

144 29) for triglycerides, and 95.0% (19/20) for low-density lipoprotein cholesterol.

145 that includes potent statin therapy and low low-density lipoprotein cholesterol.

146 igh-density-lipoprotein cholesterol (HDL-C), low-density-lipoprotein cholesterol (LDL-C), and/or trig

147 There was a significant reduction in low density lipoprotein-cholesterol (LDL-C), an increase

148 Plasma levels of total cholesterol (T-CHL), low density lipoprotein-cholesterol (LDL-CHL), and resis

149 and cardiovascular disease (CVD) context and low density lipoprotein-cholesterol concentrations withi

150 xcept for an inverse association of FT4 with low-density lipoprotein-cholesterol.

151 ed back into the cellular media, whereas the low-density lipoprotein component was localized to the l

152 n DCs on atherosclerosis were examined using low-density lipoprotein-deficient (Ldlr(-/-)) bone marro

153 players in the endosomal/lysosomal egress of low-density lipoprotein-derived cholesterol.

154 Exposure of macrophages to oxidized low-density lipoprotein downregulated LKB1 in vitro.

155 Low cholesterol and low-density lipoprotein have been associated with greate

156 with cholesterol concentrations in high- and low-density lipoproteins (HDL and LDL) particles measure

157 Blood pressure, triglycerides, low-density lipoprotein, high-density lipoprotein, and t

158 Total cholesterol, low-density lipoprotein, high-density lipoprotein, and t

159 CAD as a function of their association with low-density lipoprotein, high-density lipoprotein, trigl

160 tein component, indicating their origin from low-density lipoprotein, intermediate-density lipoprotei

161 a (FH) is characterized by severely elevated low density lipoprotein (LDL) cholesterol.

162 contributes to atherosclerosis by targeting low density lipoprotein (LDL) receptor (LDLR) degradatio

163 show that alpha2delta-1 is a ligand for the Low Density Lipoprotein (LDL) Receptor-related Protein-1

164 kinetics of key biological proteins, namely Low Density Lipoprotein (LDL), Tissue Necrosis Factor al

165 Egg yolk low density lipoprotein (LDL)/polysaccharide nanogels ar

166 Although EC are in constant contact with low density lipoproteins (LDL), how EC process LDL and w

167 Uptake of labeled low-density lipoprotein (LDL) and cholesterol was measur

168 gnificantly lowers blood pressure as well as low-density lipoprotein (LDL) and high-density lipoprote

169 95% CI, 0.80-0.95, per mmol/l increase), and low-density lipoprotein (LDL) cholesterol (OR, 0.83; 95%

170 btilisin/kexin type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipopro

171 e cardiometabolic risk-factor profile [lower low-density lipoprotein (LDL) cholesterol and triglyceri

172 e subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by appr

173 was found to produce sustained reductions in low-density lipoprotein (LDL) cholesterol levels over th

174 despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels.

175 oncern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result fr

176 l3 mRNA, Angptl3 protein, triglycerides, and low-density lipoprotein (LDL) cholesterol, as well as re

177 mes were: blood pressure, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density

178 nstrated to be associated with at least 1 of low-density lipoprotein (LDL) cholesterol, high-density

179 n-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol.

180 isin-kexin type 9 (PCSK9), reduces levels of low-density lipoprotein (LDL) cholesterol.

181 tal role in clearing atherogenic circulating low-density lipoprotein (LDL) cholesterol.

182 type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol.

183 protein and known for the endocytosis of the low-density lipoprotein (LDL) family receptors.

184 Incubation of plasma electronegative low-density lipoprotein (LDL) from UNx rats with normal

185 Electronegative low-density lipoprotein (LDL) has been shown to increase

186 ly, hepatic vigilin knockdown decreases VLDL/low-density lipoprotein (LDL) levels and formation of at

187 The low-density lipoprotein (LDL) receptor (LDLR) is a centr

188 Although sequence analysis of low-density lipoprotein (LDL) receptor (LDLR) mRNA did n

189 To this end, the low-density lipoprotein (LDL) receptor was targeted for

190 isin/kexin type 9 (PCSK9) down-regulates the low-density lipoprotein (LDL) receptor, elevating LDL ch

191 iosynthesis thereby upregulating the hepatic low-density lipoprotein (LDL) receptors and increasing t

192 Our data indicate that electronegative low-density lipoprotein (LDL) shows SMase activity, whic

193 Increased level of low-density lipoprotein (LDL) strongly correlates with i

194 Carbamylation alters low-density lipoprotein (LDL) structure and is thought t

195 ins, such as high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very-low density lipo

196 ther the most electronegative subfraction of low-density lipoprotein (LDL), L5, is correlated with QT

197 Low-density lipoprotein (LDL), one of the four major gro

198 ipid traits (high-density lipoprotein (HDL), low-density lipoprotein (LDL), plasma concentrations of

199 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol concentrations

200 CDP) on the role of non-statin therapies for low-density lipoprotein (LDL)-cholesterol lowering in th

201 HT) and its derivatives in olive oil protect low-density lipoproteins (LDL) against oxidation.

202 lied with cholesterol derived from uptake of low-density lipoproteins (LDL) and synthesis.

203 rin Efficacy International Trial by reducing low-density-lipoprotein (LDL) cholesterol levels more th

204 Low-density lipoproteins (LDLs) are a class of nanocarri

205 hages ingest high levels of damaged modified low-density lipoproteins (LDLs), generating macrophage f

206 Even after accounting for baseline low-density lipoprotein level, statin exposure continued

207 ffect persists after accounting for baseline low-density lipoprotein level.

208 (-250.19 g; 95% CI, -459.9 to -40.5 g), and low-density lipoprotein levels (-15.4 mg/dL; 95% CI, -23

209 n-1(Sort1), a known regulator of circulating low-density lipoprotein levels in humans, as a novel tar

210 After accounting for baseline low-density lipoprotein levels, persons who filled presc

211 RATIONALE: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein-like lipoprotein and important c

212 gh-density lipoprotein lipids and lower very-low-density lipoprotein lipids, glucose levels, branched

213 tein, intermediate-density lipoprotein, very-low-density lipoprotein, lipoprotein (a), or chylomicron

214 No changes in plasma levels of very low-density lipoprotein/low-density lipoprotein, high-de

215 ystemic treatment with anti-inflammatory and low-density lipoprotein-lowering drugs are currently bei

216 terol (MD -8.5 mg/dl, 95% CI -9.5, -7.4) and low-density lipoprotein (MD -2.4 mg/dl, 95% CI -3.4, -1.

217 % confidence interval 3.48-6.78), other very-low-density lipoprotein measures, and branched-chain ami

218 inhibition of PCSK9 has any effects on very low-density lipoprotein or intermediate-density lipoprot

219 induced by cholesterol crystals and oxidized low-density lipoproteins (ox-LDL), potentially by increa

220 xidative stress were measured in plasma: (1) low-density lipoprotein oxidizability, (2) high-density

221 Low-density lipoprotein oxidizability, indicative of the

222 d leads to the uptake of native and oxidized low-density lipoprotein (oxLDL) by macrophages (Mvarphis

223 Oxidized low-density lipoprotein (oxLDL) is known to activate inf

224 CD36 recognizes oxidized lipids in oxidized low-density lipoprotein (oxLDL) particles, a process tha

225 Retained oxidized low-density lipoprotein (oxLDL), in turn, stimulated myo

226 that internalize lipids, including oxidized low-density lipoprotein (oxLDL).

227 Procollagens, pre-chylomicrons, and pre-very low-density lipoproteins (pre-VLDLs) are too big to fit

228 macrophage LKB1 reduction caused by oxidized low-density lipoprotein promotes foam cell formation and

229 icantly improved high-density lipoprotein to low-density lipoprotein ratios in high fat-fed mice with

230 n signals via the lipoprotein receptors very low density lipoprotein receptor (VLDLR) and apolipoprot

231 t mice (0.162 cm(2)+/-0.023 [n=9], P2X7(-/-) low density lipoprotein receptor(-/-) : 0.084 cm(2)+/-0.

232 xpression was analyzed in aortic arches from low density lipoprotein receptor(-/-) mice consuming a h

233 P2X7(+/+) and P2X7(-/-) low density lipoprotein receptor(-/-) mice were fed a hi

234 Low density lipoprotein receptor-null (Ldlr(-/-)) mice o

235 The low density lipoprotein receptor-related protein 1 (LRP1

236 ent increases mRNA and protein expression of low density lipoprotein receptor-related protein 2 and a

237 ent and activation of beta1 integrin via the low density lipoprotein receptor-related protein-1 (LRP1

238 Mice fed a Western-type diet and lacking low-density lipoprotein receptor (Ldlr(-/-)T39(-/-)) sho

239 Female low-density lipoprotein receptor (Ldlr) deficient mice w

240 The low-density lipoprotein receptor (LDLR) plays a pivotal

241 audin-1 (CLDN1), Occludin (OCLN), SR-BI, and low-density lipoprotein receptor (LDLR), function mainly

242 ertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR), preventing its

243 As proof-of-principle, we targeted the low-density lipoprotein receptor (Ldlr), which when dele

244 the inflamed aorta in atherosclerosis-prone low-density lipoprotein receptor deficient (Ldlr(-/-)) m

245 element binding protein 2 and downregulating low-density lipoprotein receptor expression.

246 of atherogenesis by mPGES-1 deletion in the low-density lipoprotein receptor knockout mice (n=17-21)

247 inhibits atherosclerosis development in the low-density lipoprotein receptor knockout mouse.

248 with mPges-1 on a hyperlipidemic background (low-density lipoprotein receptor knockouts).

249 METHODS AND Paradoxically, Ldlr(-/-) (low-density lipoprotein receptor null) mice deficient in

250 clerotic lesion size was found in Ldlr(-/-) (low-density lipoprotein receptor null) mice transplanted

251 ion disrupts an interaction with VLDLR (very low-density lipoprotein receptor), while the APOER2 sign

252 arrow-restricted deletion of DNGR-1 in Ldlr (low-density lipoprotein receptor)-deficient mice (Ldlr(-

253 teraction with the RELN receptor VLDLR (very low-density lipoprotein receptor); this was confirmed by

254 Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one of the s

255 Tet2-mutant cells in atherosclerosis-prone, low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

256 ate senescent cells in atherosclerosis-prone low-density lipoprotein receptor-deficient (Ldlr(-/-)) m

257 od vessels invading photoreceptors: the very low-density lipoprotein receptor-deficient (Vldlr(-/-) )

258 In a low-density lipoprotein receptor-deficient atherosclerot

259 results in decreased hepatic inflammation in low-density lipoprotein receptor-deficient mice on a Wes

260 ress as prime response pathways in livers of low-density lipoprotein receptor-deficient mice on a Wes

261 Low-density lipoprotein receptor-related protein 1 (LRP-

262 Low-density lipoprotein receptor-related protein 1 (LRP1

263 , the receptors for these secreted proteins, low-density lipoprotein receptor-related protein 1 (LRP1

264 ction with the endocytic scavenger receptor, low-density lipoprotein receptor-related protein 1 (LRP1

265 ctin, a protein acting downstream from agrin/low-density lipoprotein receptor-related protein 4 (LRP4

266 ancer have identified novel functions of the low-density lipoprotein receptor-related protein 4-muscl

267 ptions of tryptophan hydroxylase 1 (Tph1) or low-density lipoprotein receptor-related protein 5 (Lrp5

268 Low-density lipoprotein receptor-related protein 6 (LRP6

269 rocytic thrombospondin-1 (TSP1) and synaptic low-density lipoprotein receptor-related protein-1 (LRP1

270 Low-density lipoprotein receptor-related protein-1 (LRP1

271 (LPS) by a pathway that apparently requires low-density lipoprotein receptor-related protein-1 (LRP1

272 rocytic thrombospondin-1 (TSP1) and synaptic low-density lipoprotein receptor-related protein-1 (LRP1

273 receptors frizzled 1-10 and the co-receptors low-density lipoprotein receptor-related proteins 5 and

274 In parallel, the low-density-lipoprotein receptor plays a predominant rol

275 els through a mechanism that is dependent on low-density lipoprotein receptors (LDLRs) and LDLR-relat

276 ntiplatelet therapy, blood pressure control, low-density lipoprotein reduction, and lifestyle modific

277 Blocking hepatic very low-density lipoprotein secretion through genetic or pha

278 echanisms and consequences of defective very low-density lipoprotein secretion.

279 inadequate increases in IHTG export via very low-density lipoprotein secretion.

280 free fatty acid oxidation, or decreased very-low-density lipoprotein secretion.

281 (standardized estimate, 0.07; P = .003), and low-density lipoprotein (standardized estimate, 0.04; P

282 links to the apolipoprotein B component of a low-density lipoprotein through a disulfide bridge to fo

283 rporation into palmitate of circulating very low-density lipoprotein triglyceride.

284 tions were observed for extremely large very-low-density lipoprotein triglycerides (odds ratio [OR] =

285 very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandia

286 sion of SRA (scavenger receptor A), modified low-density lipoprotein uptake and foam cell formation,

287 DL), low-density lipoprotein (LDL), and very-low density lipoprotein (VLDL), play a critical role in

288 notion that HCV coopts the secretion of very-low-density lipoprotein (VLDL) for its egress.

289 impaired ER-to-Golgi trafficking of pre-very low-density lipoprotein (VLDL) particles.

290 tic triglycerides (TAG) associated with very-low-density lipoprotein (VLDL) play a major role in main

291 nuation of hepatic steatosis, increased very low-density lipoprotein (VLDL) secretion, and improved g

292 prevents fructose-induced increases in very-low-density lipoprotein (VLDL) triglycerides by decreasi

293 ) for 8 weeks on the plasma kinetics of very-low-density lipoprotein (VLDL)-apolipoprotein B-100 (apo

294 d proteomic profiles implicated these 3 very-low-density lipoprotein (VLDL)-associated apolipoprotein

295 ortant for HCV cell-to-cell spread, but very-low-density lipoprotein (VLDL)-containing mouse serum di

296 erved strong positive associations with very-low-density lipoprotein (VLDL)-lipoproteins, VLDL-choles

297 Very-low-density lipoproteins (VLDL) is a hallmark of metabol

298 in (HDL) yields 4-6% of the LDL signal, very-low-density-lipoprotein (VLDL) yields 1-3%, and human se

299 lisin/kexin type 9 (PCSK9) selectively binds low-density lipoprotein; we hypothesized that it can als

300 d the hope that additional agents that lower low-density lipoprotein will decrease risk of atheroscle